GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anupam Rasayan India Ltd

Anupam Rasayan: Q2 FY27 Consolidated Revenue Rs. 821 Cr, up 11% YoY

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 06 Nov 2026, 03:48 PM IST  ·  BSE ID: 4dcbd96d-164d-4dbb-b545-42e9b94696bf
View Original BSE Filing (PDF)
💡
In Simple Terms
Anupam Rasayan reported higher sales and profits in Q2 FY27, securing a new customer deal and completing an acquisition.
🤖 AI Summary
  • Anupam Rasayan Q2 FY27 consolidated revenue was Rs. 821 Cr, an 11% increase year-on-year.
  • EBITDA for Q2 FY27 rose 41% YoY to Rs. 202 Cr, achieving an EBITDA margin of 25%.
  • Profit After Tax for Q2 FY27 stood at Rs. 65 Cr, reflecting a 14% growth from Q2 FY26.
  • Company signed a six-year long-term supply agreement with a US-based specialty metal manufacturer.
  • Successfully completed acquisition of 50.07% stake in Bliss GVS Pharma during the quarter.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total Revenue Q2 FY27
821 Rs. In Crs
11%
EBITDA Q2 FY27
202 Rs. In Crs
41%
PAT Q2 FY27
65 Rs. In Crs
14%
Total Revenue H1 FY27
1,489 Rs. In Crs
21%
EBITDA H1 FY27
377 Rs. In Crs
38%
PAT H1 FY27
116 Rs. In Crs
10%
🏢 How This Affects the Company
📈
Business Impact
The six-year supply agreement establishes Anupam Rasayan's presence in the geological resources sector and diversifies its customer base. The acquisition of Bliss GVS Pharma expands its footprint into finished dosage formulations within the pharmaceutical value chain.
💰
Financial Impact
Consolidated revenue increased by 11% YoY to Rs. 821 Cr in Q2 FY27, with PAT up 14% to Rs. 65 Cr. EBITDA margin improved to 25% for the quarter.
⚙️
Operational Impact
The Bliss GVS Pharma acquisition adds complementary capabilities and provides opportunities to leverage operational and commercial synergies across the pharmaceutical segment. Capacity is reported at ~2,00,000+ MT for Speciality Chemicals and 4,800+ Mn Units for Pharmaceutical Formulations.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the 11% YoY consolidated revenue growth and 14% YoY PAT increase in Q2 FY27.
🔍
Management Signal
Management signals a focus on strategic expansion into new end markets, strengthening business portfolios through organic growth, and inorganic acquisitions for diversification.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess sustained revenue and profit growth trends.
Updates on the integration and performance of Bliss GVS Pharma acquisition.
Further details on the six-year supply agreement's contribution to future revenue.
LOW RISK The filing indicates positive financial performance and strategic expansion without flagging immediate risks.
💡 Investor Takeaway
Anupam Rasayan reported consolidated Q2 FY27 revenue of Rs. 821 Cr, an 11% YoY increase, with PAT at Rs. 65 Cr, up 14% YoY. EBITDA grew 41% to Rs. 202 Cr. The company secured a six-year supply agreement and completed the acquisition of a 50.07% stake in Bliss GVS Pharma.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Total Revenue for Q2 FY27 grew by 11% YoY to Rs. 821 Cr, marking the highest-ever quarterly consolidated revenue.
  • EBITDA increased by 41% YoY to Rs. 202 Cr in Q2 FY27, with EBITDA margin improving to 25% for the quarter.
📅 Company Track Record
Anupam Rasayan reported Q1 FY27 consolidated revenue up 36% to ₹6,675 Mn and PAT up 6% to ₹512 Mn. The Q2 FY27 results show continued growth with consolidated revenue up 11% YoY to Rs. 821 Cr and PAT up 14% to Rs. 65 Cr.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Anupam Rasayan's consolidated revenue for Q2 FY27?
Anupam Rasayan's consolidated Total Revenue for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 821 Cr, an 11% increase compared to Q2 FY26.
What was Anupam Rasayan's Profit After Tax (PAT) in Q2 FY27?
The consolidated Profit After Tax for Anupam Rasayan in Q2 FY27 stood at Rs. 65 Cr, showing a 14% increase compared to Rs. 57 Cr in Q2 FY26.
What was Anupam Rasayan's EBITDA in Q2 FY27?
Anupam Rasayan's consolidated EBITDA for Q2 FY27 was Rs. 202 Cr, a 41% increase from Rs. 144 Cr in Q2 FY26, with an EBITDA margin of 25%.
What strategic agreements or acquisitions did Anupam Rasayan complete in Q2 FY27?
During Q2 FY27, Anupam Rasayan signed a six-year long-term supply agreement with a US-based specialty metal manufacturer and completed the acquisition of a 50.07% stake in Bliss GVS Pharma.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.